LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・Novartis AG

Novartis AG

Suletud

148.01 -1.18

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

147.68

Max

148.3

Põhinäitajad
By Trading Economics
Sissetulek	747M 3.2B
Müük	189M 14B
P/E Sektori keskmine	20.777 51.415
Aktsiakasum	1.99
Dividenditootlus	3.26
Kasumimarginaal	23.336
Töötajad	75,267
EBITDA	338M 5.4B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+14.65% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	3.26% 2.34%

Turustatistika
By TradingEconomics
Turukapital	-1.2B 277B
Eelmine avamishind	149.19
Eelmine sulgemishind	148.01

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

N/A / 112.63 Toetus ja vastupanu

Novartis AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. apr 2026, 09:05 UTC

Tulu

Novartis Earnings Hit by Generic Competition -- Update

28. apr 2026, 05:51 UTC

Tulu

Novartis Could Upgrade Future Growth Outlook

27. märts 2026, 10:24 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27. märts 2026, 06:36 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28. apr 2026, 09:18 UTC

Market Talk

Tulu

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28. apr 2026, 07:26 UTC

Market Talk

Tulu

Novartis's Results Are Mixed -- Market Talk

28. apr 2026, 05:07 UTC

Tulu

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28. apr 2026, 05:05 UTC

Tulu

Novartis: On Track to Deliver Full-Year Guiance

28. apr 2026, 05:04 UTC

Tulu

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28. apr 2026, 05:04 UTC

Tulu

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28. apr 2026, 05:03 UTC

Tulu

Novartis 1Q Core EPS $1.99

28. apr 2026, 05:03 UTC

Tulu

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28. apr 2026, 05:02 UTC

Tulu

Novartis 1Q Core Operating Profit $4.90B

28. apr 2026, 05:02 UTC

Tulu

Analysts Saw Novartis 1Q Sales at $13.34B

28. apr 2026, 05:01 UTC

Tulu

Novartis 1Q Sales $13.11B

28. apr 2026, 05:00 UTC

Tulu

Novartis Backs 2026 View

28. apr 2026, 05:00 UTC

Tulu

Novartis AG 1Q EPS $1.65

28. apr 2026, 05:00 UTC

Tulu

Novartis AG 1Q Net Pft $3.2B

28. apr 2026, 05:00 UTC

Tulu

Novartis AG 1Q Adj EPS $1.99

24. apr 2026, 05:20 UTC

Tulu

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24. apr 2026, 05:19 UTC

Tulu

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24. apr 2026, 05:19 UTC

Tulu

Novartis: Prequalification Is a Process Run by the WHO

10. apr 2026, 11:45 UTC

Market Talk

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2. apr 2026, 08:01 UTC

Market Talk

Novartis Likely to Confirm Guidance -- Market Talk

30. märts 2026, 09:37 UTC

Market Talk

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27. märts 2026, 07:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27. märts 2026, 06:22 UTC

Omandamised, ülevõtmised, äriostud

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27. märts 2026, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27. märts 2026, 06:04 UTC

Omandamised, ülevõtmised, äriostud

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27. märts 2026, 06:03 UTC

Omandamised, ülevõtmised, äriostud

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Võrdlus sarnastega

Hinnamuutus

Novartis AG Prognoos

Hinnasiht

By TipRanks

14.65% tõus

12 kuu keskmine prognoos

Keskmine 169.78 USD 14.65%

Kõrge 180 USD

Madal 141 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Novartis AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Novartis AG aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 112.63Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.